慢性粒细胞白血病2011nccn指南

Chronic Myelogenous Leukemia
Table of Contents
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) – Version 2.2011
Table of contents
PANEL MEMBERS ................................................................................................................................................................................................................................................ 1 SUMMARY OF THE GUIDELINES UPDATES ..................................................................................................................................................................................................... 2 CHRONIC MYELOGENOUS LEUKEMIA ............................................................................................................................................................................................................. 4 DISEASE PROGRESSION.......................................................................................................................................................................................................................... 9 HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) ............................................................................................................................................................... 10 MONITORING FOR PATIENTS RECEIVING TYROSINE KINASE INHIBITOR THERAPY .................................................................................................................... 11 SUPPORTIVE CARE STRATEGIES FOR LEUKOCYTOSIS AND THROMBOCYTOSIS ....................................................................................................................... 13 MANAGEMENT OF IMATINIB TOXICITY ................................................................................................................................................................................................. 14 MANAGEMENT OF NILOTINIB TOXICITY ............................................................................................................................................................................................... 16 IMPORTANT CONSIDERATIONS WITH NILOTINIB ............................................................................................................................................................................... 17 MANAGEMENT OF DASATINIB TOXICITY ............................................................................................................................................................................................. 18 CRITERIA FOR CYTOGENETIC, HEMATOLOGIC AND MOLECULAR RESPONSE ............................................................................................................................ 19 MANAGEMENT OF INTERFERON TOXICITY ......................................................................................................................................................................................... 20 DEFINITIONS OF ACCELERATED PHASE ............................................................................................................................................................................................. 21 DEFINITIONS OF BLAST CRISIS ............................................................................................................................................................................................................. 23 NCCN CATEGORIES OF EVIDENCE AND CONSENSUS................................................................................................................................................................................ 25 DISCUSSION ...................................................................................................................................................................................................................................................... 26
Printed by wang xiaobao on 3/24/2011 10:48:53 AM. For personal use only. Not approved for distribution. Copyright © 2011 National Comprehensive Cancer Network, Inc., All Rights Reserved.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™)
Chrowenku.baidu.comic Myelogenous Leukemia
Version 2.2011 NCCN.org
The NCCN Guidelines™ are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2011. 02/15/11